Hepatitis C virus (HCV) is a common infection worldwide, and in most persons, it leads to persistent viremia and liver damage. Efforts to identify the correlates of protective immunity are hampered by this high rate of persistent infection in both infected humans and the only animal model, the chimpanzee. Peripheral blood mononuclear cells from seronegative persons were stimulated with synthetic peptides that represent epitopes recognized by HCV-specific cytotoxic T lymphocytes (CTL) after natural infection. In addition, CD4
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/ proliferative responses to recombinant HCV proteins were examined in these same persons. CTL responses directed against a peptide epitope of HCV and proliferative responses in 2 HCV-seronegative persons with possible occupational exposure to HCV were found. These otherwise healthy persons were not viremic, suggesting that they may have recovered from acute HCV infection. Characterization of virus-specific immune responses in exposed but seronegative persons may provide important clues as to the nature of protective immunity in HCV.
Hepatitis C virus (HCV) continues to cause a major proporprotective immunity in the only animal model of HCV infection, the chimpanzee, and by the high rate of chronicity among tion of chronic liver disease worldwide despite the advent of highly efficacious blood-screening programs to reduce transfuinfected persons. It is likely that cellular immune responses play a critical role in protective immunity as well as in controlsion-associated transmission [1] . Current estimates are that in the United States alone 1.5% -4.4% of the general population ling viral replication. Recent evidence suggests that a quantitatively more vigorous CD4 / proliferative T cell response to one is seropositive for antibodies to HCV. Infection with HCV progresses to chronic liver disease in at least 50% of infected or more HCV antigens may be associated with a healthy carrier state or complete recovery from HCV infection [7 -9, 34]. persons [2] , and a high proportion of the remainder are viremic even without overt clinical evidence of liver destruction [3] .
Studies of the cytotoxic T lymphocyte (CTL) response have failed to show a clear correlation between HCV-specific CTL In juxtaposition, certain individuals have sustained exposure to HCV without apparent infection. For example, HCV transresponses and clearance of infection. In chronically infected persons, multiple proteins serve as targets of the CTL response, mission through sexual intercourse is inefficient in the absence of human immunodeficiency virus (HIV) coinfection [4] , as is yet virus persists [10 -13]; however, it has been suggested that a positive CTL response may be associated with lower titers vertical transmission [5] . Among intravenous drug users, up to 80% of a given cohort may seroconvert to anti-HCV when of virus [14 -16] . As with hepatitis B virus infection, investigators have been followed over 10 years; however, among the remaining 20%, there is no seroconversion, despite repeated exposure to the unable to detect HCV-specific CTL in peripheral blood mononuclear cells (PBMC) without specific antigenic stimulation, virus through needle-sharing and sexual exposure [6] . This suggests that there may be large numbers of persons who are usually by peptides that bind to HLA molecules with high affinity [12, 17 -19] . In the course of studying HCV-specific repetitively exposed and who may possibly develop protective immunity.
CTL responses in the PBMC, we identified 2 persons with likely occupational exposure to HCV who appear to have HCVAttempts to identify the correlates of protective immunity in HCV infection have been hampered by an apparent lack of specific CD4 / and CD8 / responses in the absence of either a humoral response or viremia. In this report, we describe for the individual subjects the immune responses that suggest possible exposure to HCV without the development of chronic infection. multiple primers, including primers from the highly conserved 5 10% dimethyl sulfoxide and 1 mM dithiothreitol (both from Sigma). untranslated region, HCV core, and NS5 [20] [21] [22] [23] . Subjects A and B were repeatedly negative for serum HCV RNA, whereas HCVRecombinant HCV antigens. The HCV proteins core, E1, E2, infected subjects with chronic infection were positive for serum NS3, NS4, and NS5 were expressed as C-terminal fusions with human HCV RNA with any of the primer sets (Koziel MJ, unpublished superoxide dismutase (SOD) in yeast (Saccharomyces cervisiae) and data). Neither subject recalled specific exposure to HCV-infected purified as described [8] . Recombinant tetanus toxoid (TT), candida source material, but they had worked in urban medical centers and (both from Connaught, Swiftwater PA), and superoxide dismutase had each sustained at least one needlestick injury. The last known antigens were used as positive or negative controls. percutaneous exposure for subjects A and B was 5 and 3 years, Stimulation of PBMC with synthetic peptides. PBMC were respectively, prior to these studies. In addition, each subject was isolated by ficoll-hypaque density gradient centrifugation (Sigma), in a stable monogamous sexual relationship with a non-HCVwashed twice in RPMI 1640, and resuspended at 4 1 10 6 cells/ infected partner, had never used intravenous drugs or intranasal mL in RPMI 1640 supplemented with 2 mM L-glutamine, 50 U/ cocaine, and had no known immunosuppressive condition. None mL penicillin, 50 mg/mL streptomycin, and 10 mM HEPES conof the other subjects had any risk factors for HCV exposure and taining 10% heat-inactivated human AB serum (R-10AB). Peptide were not immunosuppressed.
stimulations were done according to the protocol of Cerny et al.
Cell lines. Epstein-Barr virus-transformed B-lymphoblastoid
[12]. Peptides, which were chosen on the basis of the HLA haplocell lines (B-LCL) were established and maintained as previously type of the individual subjects being tested, were known to repredescribed [24] in R-20 medium (RPMI 1640 [Sigma, St. Louis] sent epitopes recognized by CTL from persons with chronic HCV supplemented with 2 mM L-glutamine, 50 U/mL penicillin, 50 mg/ or HIV-1 infection (table 2) . Peptides (final concentration, 10 mg/ mL streptomycin, 10 mM HEPES, and 20% heat-inactivated fetal mL) were added to the cells (4 1 10 6 in a 24-well plate), and TT calf serum). Additional B-LCL were obtained from the American was added at a final concentration of 1 mg/mL. On day 3, 1 mL Society for Histocompatibility and Immunogenetics B cell line of R-10AB supplemented with 20 U/mL recombinant interleukin repository (Brigham and Women's Hospital, Boston).
(IL)-2 (provided by Maurice Gately, Hoffman-La Roche, Nutley, HLA typing. HLA typing of subjects was done on fresh PBMC NJ) was added. On day 7, the cell population was stimulated with by the Massachusetts General Hospital Tissue Typing Laboratory, 4 1 10 6 autologous PBMC in fresh R-10AB supplemented with using standard serologic techniques. The HLA type of the subjects 10 mg/mL synthetic peptide, 1 mg/mL TT, and 20 U/mL IL-2. is shown in table 1.
Cells were tested for cytolytic activity on day 14 of culture. For bulk cultures in which peptide-specific activity was detected, Vaccinia virus (vv) constructs. vv-C/E1 was used to express aa met 1 -ile 340 of HCV, which comprise the core (C) and E1 proclones were derived after stimulation with irradiated allogeneic feeder cells and the anti-CD3 monoclonal antibody 12F6, as deteins, and a vv expressing only the Escherichia coli b-galactosidase gene (vv-Lac) was used as a control [25] .
scribed [30] , without further need for peptide stimulation. Cytotoxicity assay. B-LCL were pelleted, resuspended in fresh Synthetic peptides. All of the peptides represent epitopes that are recognized by CTL isolated from persons with either chronic R-20, and labeled overnight with Na 2 ( 51 CrO4). Cells (1 1 10 6 ) were then resuspended in 0.2 mL of RPMI 1640 supplemented HCV or HIV-1 infection. Synthetic peptides corresponding to the amino acid sequences of the HCV-1 isolate of Choo et al. [26] or with glutamine, antibiotics, HEPES, and 10% heat-inactivated fetal calf serum (R-10), and peptide (10 mg/mL) was added. After a 1-to HIV-1 isolate LAI [27] were synthesized as free acids by Cambridge Research Biochemicals (Cambridge, MA), using the FMOC h incubation at 37ЊC, cells were washed three times and used as targets (5 1 10 3 cells/well) in the cytotoxicity assay. Supernatants method. The peptides used for this study are shown in table 2. All peptides were reconstituted in sterile distilled water containing were harvested at 4 h, and the percent specific cytotoxicity was / 9d35$$oc45 08-18-97 11:23:42 jinfal UC: J Infect followed by limiting dilution cloning in the absence of specific Kalams [31] ) by plotting the log of the fraction of negative wells antigenic stimulation [30] . In each case, these CTL lines or (F n ) versus the number of input wells and solving for F n Å 0.37, using the maximum likelihood method [32] .
clones recognized only B-LCL expressing HLA 35, which were sensitized with E234 not Env 611, and not non-HLA -matched B-LCL (figure 1 and data not shown). PBMC for 8 additional Results seronegative control subjects were also stimulated with one or more synthetic peptides (table 2) , and in no case was peptide-HCV-specific cytolytic T cells in seronegative persons. PBMC from healthy HCV-and HIV-1 -seronegative persons specific CTL activity detected (data not shown).
/ 9d35$$oc45 08-18-97 11:23:42 jinfal UC: J Infect Since it is possible that primary immune responses may be CTL p of all other targets was õ1/590,000 (data not shown). From both subjects A and B, it was also possible to derive generated using TT as a source of T cell help, PBMC from subject A were stimulated with peptide, TT, and IL-2; peptide HCV E234 -specific clones from the stimulated cultures, using only an anti-CD3 monoclonal antibody as a nonspecific source and IL-2; or TT and IL-2. Although in all cases HCV E234 -specific CTL lines could be generated, this activity was present of T cell stimulation, and ongoing peptide-specific stimulation was not required [30] (data not shown). even in the absence of peptide ( figure 1D ), which suggests that the cytolytic activity was not secondary to in vitro priming.
HCV-specific proliferative responses in seronegative persons. T cell proliferative responses to HCV and control antigens were Limiting dilution analysis was done for subjects A and B and a control subject to estimate the precursor frequency (CTL p ) of measured in 9 subjects (table 3). All subjects had an SI ú2.0 to two or more control antigens. However, only subjects A and B, HCV E234 -specific CTL. As shown in figure 2, subject A had a high frequency of HCV E234 -specific CTL compared with who also had E234-specific responses, demonstrated specific proliferative responses against one or more recombinant HCV prothat for the control subject and compared with CTL specific for the control peptides. The CTL p after HCV E234 stimulation teins. Positive responses were retested with variable amounts of antigen on multiple occasions, and increasing amounts of antigen of PBMC from this subject was 1/11,391, compared with õ1/ 70,000 for all other peptides. Similarly, the CTL p of all peptideresulted in more vigorous SIs in the positive responders, whereas subjects C-I had SIs õ2.0 even when the concentration of antigen specific CTL was õ1/57,000 for the control subject. For subject B, the CTL p of E234-specific cells was 1/85,000, whereas the was raised to 10 mg/mL (data not shown).
/ 9d35$$oc45 08-18-97 11:23:42 jinfal UC: J Infect Figure 2 . Analysis of cytotoxic T lymphocyte (CTL) precursor frequency after peptide (pep) stimulation (stim). Peptidespecific CTL precursor frequencies were analyzed by limiting dilution analysis in subjects A (A) and control subject (B) as described in Materials and Methods. Concentration of peptide used to sensitize target cells was 10 mg/mL. Results are shown as semilogarithmic plot of responder cell input per well vs. % negative wells. Neg Resp Å negative response, E Å envelope protein, C Å core, F n Å fraction of negative wells.
Discussion more HCV proteins. This epitope was identified by CTL from liver-infiltrating lymphocytes of a person with chronic HCV In this report, we describe CTL responses directed against a infection and was not chosen on the basis of binding to purified peptide epitope of HCV and proliferative responses in 2 persons HLA B35 molecules or a sequence motif [25] ; thus, it is clear with possible occupational exposure to HCV. Testing over a 12-that this is an epitope that is presented in natural HCV infection month period revealed that neither individual seroconverted nor in the context of HLA B35. This HCV E1 epitope does bind developed viremia. These persons were repeatedly tested for the to purified HLA 35*01, although with lower affinity than the presence of anti-HCV antibodies by use of a second-generation peptides used in most studies [12] (Sidney J, personal commu-ELISA assay thought to be highly sensitive and for HCV RNA nication). HCV E1-specific CTL could be isolated after two by use of multiple primers against well-conserved regions of the rounds of stimulation with peptide, and in one case with TT virus. Since these persons were clinically well, liver tissue was only and no specific peptide stimulation. not available; therefore, the presence of virus in the liver tissue
The HCV-specific CTL lines and clones obtained from subcannot be definitively excluded. However, on the basis of comjects A and B had high levels of peptide-specific activity yet monly accepted criteria for HCV infection, these persons did not failed to recognize endogenously processed proteins (data not appear to have ongoing HCV infection.
shown). This failure to recognize target cells expressing endogDespite the absence of HCV-specific humoral responses and enously processed HCV proteins has been reported by other virus, these persons had CTL responses directed against an investigators who have used this stimulation strategy, and it may be due to the selection of CTL with low avidity for the epitope in HCV E1 and proliferative responses against two or / 9d35$$oc45 08-18-97 11:23:42 jinfal UC: J Infect peptide-HLA complex [12] . These same subjects had CD4 / T A second possibility is that these CTL responses represent cross-reactive responses against heterologous proteins. Since cell responses against several HCV proteins, even when the criterion for a positive response was an SI cutoff of 4. The the CTL recognizes viral protein as part of a complex consisting of the HLA molecule and a peptide fragment, a peptide fragcomplete absence of a humoral response by what is thought to be a highly sensitive assay remains unexplained; however, ment generated from proteolytic degradation of any protein with sufficient homology to this sequence could have primed healthy carriers of HCV appear to have a weak humoral and strong T helper response against HCV compared with that for the immune response in these persons. Cross-reactivity of CTL responses against heterologous proteins has been reported [38, persons with chronic liver disease caused by HCV [34] . 39]. Although in many circumstances cross-reactivity has been There are several possible reasons for the presence of HCVnoted to be on the basis of sequence homology, in others the specific immune responses in otherwise seronegative persons.
cross-reactivity was not due to homologous sequences [40] . The first explanation is that these responses represent primary An extensive search for this sequence in the SWISSPROT and in vitro responses and have no meaning in terms of relevance to European Molecular Biology Laboratory databases failed to HCV pathogenesis. The use of peptides that represent potential reveal any other source for the peptide sequence NASRCWepitopes to stimulate PBMC responses has been used to define VAM other than HCV, but the CTL responses could have been CTL epitopes recognized in both acute and chronic HBV infecprimed by another viral infection or exposure to antigen. The tion, using peptides that bind tightly to HLA molecules and presence of vigorous HCV-specific CD4 / responses suggests hepatitis B core antigen as a source of T cell help [35, 36] .
that the CTL response to HCV was not solely due to molecular This approach has been adopted by others to facilitate identifimimicry and that there was at least a transient infection from cation of CTL epitopes in chronic HCV infection [12, 17 -which these persons recovered. A preexisting immunity to an -19] . However, at least 1 of these groups has also reported the other infectious agent could have provided some level of propresence of CTL responses against peptides in seronegative tective immunity against HCV that facilitated recovery from subjects, although estimates of the precursor frequency of the acute HCV infection. response in seronegative versus seropositive persons revealed a log or more difference in CTL precursor frequency, and A third possibility is that these immune responses may represent persons who have been exposed to HCV but cleared the generation of primary responses required multiple rounds of stimulation in vitro [12, 37] . However, in the subjects reported infection. The subjects had robust T helper cell responses against HCV. Several groups have recently reported that a T in our study, HCV peptide -specific responses were identified after only two rounds of stimulation, and other HLA B35 -helper cell response against one or more HCV antigens that is quantitatively more vigorous than that for chronically infected positive persons did not have a peptide-specific response. Of additional significance is the existence of HCV-specific prolifpersons facilitates recovery from acute HCV [7 -9, 34]. To date, no group has reported CTL responses in persons who erative responses, which would seem to indicate that two arms of the acquired immune system were activated. HIV-specific CTL responses [41, 42] . Among commercial sex cleared or were never infected. The presence of both CTL and
